Structure of adeno-associated virus-2 in complex with neutralizing monoclonal antibody A20

被引:72
作者
McCraw, Dustin M. [1 ]
O'Donnell, Jason K. [2 ]
Taylor, Kenneth A. [3 ]
Stagg, Scott M. [2 ,4 ]
Chapman, Michael S. [1 ]
机构
[1] Oregon Hlth & Sci Univ, Sch Med, Dept Biochem & Mol Biol, Portland, OR 97239 USA
[2] Florida State Univ, Inst Mol Biophys, Tallahassee, FL 32306 USA
[3] Florida State Univ, Dept Biol Sci, Tallahassee, FL 32306 USA
[4] Florida State Univ, Dept Chem & Biochem, Tallahassee, FL 32306 USA
基金
美国国家卫生研究院;
关键词
Adeno-associated virus; Antibody; A20; Epitope; Fab'; Gene therapy; Monoclonal; AAV2 CAPSID GENE; ELECTRON-MICROSCOPY; IMMUNE-RESPONSES; RECEPTOR-BINDING; VIRAL VECTORS; FACTOR-IX; TRANSDUCTION; THERAPY; PARVOVIRUS; IDENTIFICATION;
D O I
10.1016/j.virol.2012.05.004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The use of adeno-associated virus (AAV) as a gene therapy vector is limited by the host neutralizing immune response. The cryo-electron microscopy (EM) structure at 8.5 angstrom resolution is determined for a complex of AAV-2 with the Fab' fragment of monoclonal antibody (MAb) A20, the most extensively characterized AAV MAb. The binding footprint is determined through fitting the cryo-EM reconstruction with a homology model following sequencing of the variable domain, and provides a structural basis for integrating diverse prior epitope mappings. The footprint extends from the previously implicated plateau to the side of the spike, and into the conserved canyon, covering a larger area than anticipated. Comparison with structures of binding and non-binding serotypes indicates that recognition depends on a combination of subtle serotype-specific features. Separation of the neutralizing epitope from the heparan sulfate cell attachment site encourages attempts to develop immune-resistant vectors that can still bind to target cells. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:40 / 49
页数:10
相关论文
共 72 条
[1]  
Agbandje-McKenna M., 2006, PARVOVIRUSES, P124
[2]  
Agbandje-McKenna M, 2011, METHODS MOL BIOL, V807, P47, DOI 10.1007/978-1-61779-370-7_3
[3]  
BLACKLOW NR, 1968, JNCI-J NATL CANCER I, V40, P319
[4]   Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors [J].
Boutin, Sylvie ;
Monteilhet, Virginie ;
Veron, Philippe ;
Leborgne, Christian ;
Benveniste, Olivier ;
Montus, Marie Francoise ;
Masurier, Carole .
HUMAN GENE THERAPY, 2010, 21 (06) :704-712
[5]   Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration [J].
Brockstedt, DG ;
Podsakoff, GM ;
Fong, L ;
Kurtzman, G ;
Mueller-Ruchholtz, W ;
Engleman, EG .
CLINICAL IMMUNOLOGY, 1999, 92 (01) :67-75
[6]   Crystallography & NMR system:: A new software suite for macromolecular structure determination [J].
Brunger, AT ;
Adams, PD ;
Clore, GM ;
DeLano, WL ;
Gros, P ;
Grosse-Kunstleve, RW ;
Jiang, JS ;
Kuszewski, J ;
Nilges, M ;
Pannu, NS ;
Read, RJ ;
Rice, LM ;
Simonson, T ;
Warren, GL .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1998, 54 :905-921
[7]   Adeno associated viral vectors for gene transfer and gene therapy [J].
Büeler, H .
BIOLOGICAL CHEMISTRY, 1999, 380 (06) :613-622
[8]   Worldwide Epidemiology of Neutralizing Antibodies to Adeno-Associated Viruses [J].
Calcedo, Roberto ;
Vandenberghe, Luk H. ;
Gao, Guangping ;
Lin, Jianping ;
Wilson, James M. .
JOURNAL OF INFECTIOUS DISEASES, 2009, 199 (03) :381-390
[9]  
Carter B. J., 2008, GENE CELL THERAPY TH, P115
[10]  
Carter BJ, 1996, CURR TOP MICROBIOL, V218, P119